Drugs / CBT124
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02879097 | Dec 2016 → Dec 2017 | non-small cell lung carcinoma | Cipla BioTec Pvt. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBT124 | “CBT124 15 mg/kg IV infusion” NCT02879097 ↗ |
| Known as | bevacizumab | “receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle)” NCT02879097 ↗ |
| Route | Intravenous | “CBT124 15 mg/kg IV infusion” NCT02879097 ↗ |